the RAND study, most studies had reported a female-to-male preponderance of IC/BPS of 5: 1 or greater, 6 suggesting that this condition may be underdiagnosed and undertreated in the male population. 5 Using the O'Leary-Sant symptom and problem index to select women with IC, Leppilahti et al. reported an estimated prevalence of IC/BPS was 300 per 100 000. 7, 8 Similar studies suggested an overall prevalence of IC/BPS was 306 per 100 000 in Austrian women 9 and 265 per 100 000 in Japanese women. 10 Using the Bristol Female Lower Urinary Tract Symptoms questionnaire, Song et al. reported that the prevalence of BPS symptoms for Fuzhou Chinese women was 98 per 100 000. 11 
| DIAGNOSIS OF IC/BPS
The diagnosis of IC/BPS can be challenging and difficult for clinicians.
Because patients present with a wide range of symptoms, physical examination findings, and clinical test results, they may be misdiagnosed or underdiagnosed, or diagnosis may be delayed. 12 Symptom scores, such as the O'Leary-Sant symptom and problem index, may help assess patients and act as outcome measures. Rigid cystoscopy under a general anesthetic should be performed in patients with bladder pain. After excluding specific diseases, patients with symptoms according to the definition of AUA should be diagnosed with IC/BPS according to subtype and phenotype. 13 
| CURRENT INTRAVESICAL THERAPY FOR IC/BPS
Treatment strategies for IC/BPS should start with more conservative therapies first, proceeding to less conservative therapies if symptom control is not adequate and/or the patient's quality of life (QoL) is unacceptable. It has been suggested that appropriate manual physical therapy techniques be offered to patients who present with pelvic floor tenderness. 3 Although oral medication, such as amitriptyline, cimetidine, hydroxyzine, or pentosan polysulfate, has been used to relieve the symptoms of IC/BPS in patients, the role of oral medication in IC/BPS is to support other forms of treatment. 14 Given that the pathogenesis of IC/BPS has been proposed as a wounded uroepithelium that induces a subsequent inflammatory reaction and sensory symptoms, it would be reasonable to assume that it would be best to apply medication directly in the bladder where it hurts. Intravesical instillation has been accepted as standard treatment for IC/BPS because it offers the following advantages: (i) a higher drug concentration in the bladder; (ii) reduced systemic side effects; (iii) reduced the drug-drug interactions caused by oral medications, which may affect efficacy; and (iv) directly repairs the urothelium defect. 15 However, intravesical drug delivery may be inadequate because of the impermeability of urothelial cells with tight junctions and umbrella cells on the apical surface, a short duration of action, and the need for frequent administration, which can be painful, costly, and associated with the risk of infection. 13, 16 Because of the multifactorial nature of the disease, multimodal treatment of IC/BPS through intravesical approaches acting through different mechanisms may improve therapeutic outcomes. 17 Below, we review of literature describing the status of current and novel intravesical therapy for IC/ BPS ( Figure 1 ).
Several drugs and chemicals have been suggested to be effective for the treatment of IC/BPS, namely heparin, heparinoids such as hyaluronic acid, chondroitin sulfate, and PPS (Elmiron; Janssen, NJ), dimethylsulfoxide (DMSO), and botulinum onabotulinumtoxinA (BoNT-A). Table 1 summarizes results of intravesical therapy for IC/ BPS in controlled and uncontrolled trials.
| Heparin
Weaver et al. 36 first reported the use of intravesical therapy for the treatment of IC. Heparin has the ability to mimic the GAG lining of the bladder itself. 37 It has anti-inflammatory effects and may also Unless indicated otherwise, data are given as the mean AE SD. Pain was assessed using a 10-point visual analog scale (VAS). a Results at 6 weeks.
b Results at 24 weeks.
c Intravesical instillation with 300 mg (3 capsules) Elmiron mixed with 50 mL of 0.9% sodium chloride.
d Two hundred milligrams or 2 capsules mixed with 30 mL sterile normal buffered saline.
3 months. 44 After treatment, 29 patients had a symptom score improvement of >50% and 8 patients had a symptom score improvement <50% but improved nocturia. 44 Parsons also showed that intra- 45 
| Hyaluronic acid
The GAG layer of the urothelium functions as an epithelial permeability barrier. When impaired, its functions can be duplicated by exogenous GAG. As a natural component of the GAG layer, hyaluronic acid (HA) was used to repair detects of the GAG layer of the urothelium. 37 HA may reduce the permeability of the synovial membrane and inhibit the chemotactic and phagocytic functions of leukocytes. 46 Morales et al. 18 21 concluded that there was no significant difference in the therapeutic effect between the 2 HA instillation regimens. Generally, HA intravesical therapy has a good response rate, ranging from 69% to 93% [18] [19] [20] [21] [22] [23] [24] (Table 1 ).
| Chondroitin sulfate
Chondroitin sulfate (CS) is also a component of the GAG layer. A deficit of CS proteoglycans in the bladder uroepithelium has been detected in IC/BPS patients. 48 Like HA, CS has been used as in intravesical instillation therapy for PBS/IC patients. 33 In another study, Davis et al. 34 examined the safety and efficacy of a combination of intravesical and oral PPS compared with oral only PPS in treating IC/BPS. A total of 41 women diagnosed with IC/BPS were treated with combination therapy or oral PPS alone for 6 weeks, with all subjects continuing to receive oral PPS for another 12 weeks. At Week 18, the combination treatment group showed a significant improvement in all health-related QoL domains compared with the baseline. 34 The authors of that study concluded that intravesical PPS simultaneously with oral PPS is a safe and effective therapeutic option. Based on these studies, it appears that the combination of intravesical and oral PPS has a higher response rate than intravesical PPS alone.
31,32,34
| Dimethylsulfoxide
The mechanism underlying the effects of DMSO in relieving the symptoms of IC/BPS is assumed to be a combination of anti-inflammatory effects, nerve blockade, smooth muscle relaxation, and collagen inhibition. 1, 51 In clinical use, DMSO can be instilled weekly, with 50 mL of 50% w/w DMSO administered via bladder catheter for 6 weeks. 35, 53 Five clinical studies have investigated the efficacy of DMSO therapy in combination with heparin, hydrocortisone, triamcinolone, and/or local anesthetic, known as "cocktail" preparations, with response rates ranging from 61% to 70% over up to 13 months of follow-up. [54] [55] [56] [57] [58] However, the efficacy in these studies did not exceed the outcomes seen with DMSO alone, indicating that there was no benefit with the "cocktail" therapy.
Treatment relapse after a series of DMSO instillations is common. For patients who initially respond to DMSO therapy, a repeat series of 6 instillations may be necessary. Other therapies, such as intravesical lidocaine, intravesical heparin, or more invasive therapies, can be tried if patients fail to respond to repeated doses of DMSO. saline group (63% vs 15%, respectively; P = .028). 67 Giannantoni et al. Giannantoni et al. 68 concluded that repeat injections of the neurotoxin are required for efficacious treatment in patients with the disease.
BoNT-A has been designated as the fourth-line treatment for IC/BPS by the AUA IC/BPS Guideline Panel. 3 The panelists suggested a major shift in how BoNT-A is administered to treat IC/BPS in several ways, including combination of BoNT-A with hydrodistension, the use primarily of the 100-U dose, the use of repeat treatments with symptom return, and following-up patients for years rather than months. 3 A very recent meta-analysis showed that BoNT-A therapy has the highest probability of being the best therapy according to global response assessment, and significantly improves bladder capacity in IC/BPS patients. was though to be a significant placebo effect. 79 Further clinical trials with different protocols are needed to confirm the efficacy of LipoBoNT-A in treating IC/BPS. 
| Liposomal tacrolimus

| Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF)-driven processes in bladder urothelial cells and ganglia during the course of inflammation have been established. 82 Cheppudira et al. 83 also demonstrated that urinary bladder inflammation and NGF regulate the VEGF receptor system in the urinary bladder. Bladder instillation of a targeted fluorescent tracer, an engineered single-chain VEGF labeled with Cy5.5 dye (scVEGF/Cy), showed preferential accumulation at sites of bladder inflammation and in ganglia. 84 Therefore, increased angiogenesis at sites of inflammation and ulcers in IC/PBS can be targeted with ligands for the VEGF receptor. 82 
| Continuous intravesical lidocaine
According to the latest European Association of Urology (EAU) guidelines for chronic pelvic pain, 85 lidocaine could to treat IC/BPS in combination with heparin and sodium bicarbonate. There are sporadic reports of successful treatment of BPS with intravesical lidocaine. 88 Alkalization of lidocaine improves its pharmacokinetics. Intravesical instillation of alkalized lidocaine or placebo for 5 consecutive days resulted in significantly sustained symptom relief for up to 1 month. 88 Using elastomeric polymers, a continuous lidocaine-releasing intravesical system (LiRIS) was designed to be retained in the bladder through cystoscopy and to release therapeutic amounts of the drug into the urine over a period of 2 weeks. 86 In the LiRIS, lidocaine is contained in powdered form with baseline. 86 Extended follow-up suggested that the reduction in pain was maintained for several months after the device was removed.
Both doses were well tolerated. The unexpected longer duration of effects and healing of ulcers could be due to the anti-inflammatory actions of lidocaine over the 14-day treatment period.
| CONCLUSION
IC/BPS is a complicated condition caused by multiple etiologies and pathological pathways. It is still a pathophysiological enigma and considered a multifactorial process that ends with an imbalance in the damage repair process in the urothelium, leading to a deficiency of the GAG layer and subsequent symptoms. From abnormal urothelial permeability, sensory nerve stimulation, and to mast cell activation, this complex process contributes to the severity and unsatisfactory responses of IC/BPS to treatment. Despite extensive empirical use of intravesical agents, the evidence for efficacy is the early phases.
Although some intravesical agents, such as GAG analogs and DMSO, have shown promise in relieving symptoms of IC/BPS (Table 1) 
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